Admission glucose level and short-term mortality in older patients with acute myocardial infarction: results from the KORA myocardial infarction registry by Mamadjanov, Temur et al.
1Mamadjanov T, et al. BMJ Open 2021;11:e046641. doi:10.1136/bmjopen-2020-046641
Open access 
Admission glucose level and short- term 
mortality in older patients with acute 
myocardial infarction: results from the 
KORA Myocardial Infarction Registry
Temur Mamadjanov   ,1,2 Konstantinos Volaklis,2 Margit Heier,3,4 Dennis Freuer,2 
Ute Amann,5 Annette Peters,3 B Kuch,6 Christian Thilo,7 Jakob Linseisen,2,5 
Christa Meisinger2
To cite: Mamadjanov T, 
Volaklis K, Heier M, et al.  
Admission glucose level 
and short- term mortality in 
older patients with acute 
myocardial infarction: results 
from the KORA Myocardial 
Infarction Registry. BMJ Open 
2021;11:e046641. doi:10.1136/
bmjopen-2020-046641
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
046641).
Received 11 November 2020
Accepted 20 May 2021
For numbered affiliations see 
end of article.
Correspondence to
Temur Mamadjanov;  
 temurmamadjanov@ gmail. com
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Study objectives To investigate the association between 
admission blood glucose levels and 28- day mortality as 
well as in- hospital complications in older patients with 
incident acute myocardial infarction (AMI) undergoing 
modern treatment.
Methods From a German population- based regional MI 
registry, 5530 patients (2016 women), aged 65–84 years, 
hospitalised with an incident AMI between 1 January 
2009 and 31 December 2016 were included in the study. 
Multivariable logistic regression models were used to 
assess the associations between admission blood glucose 
and 28- day mortality as well as in- hospital complications 
after AMI. Analyses stratified according to age, diabetes 
and type of infarction (ST- elevation MI (STEMI)/non- STEMI) 
were conducted.
Results The adjusted ORs for the association between 
admission blood glucose and 28- day mortality in young- 
old (65–74 years) and old (75–84 years) patients with 
AMI were 1.40 (95% CI: 1.21 to 1.62) and 1.21 (95% 
CI: 0.98 to 1.50) per 1 SD increase in admission blood 
glucose, respectively. Furthermore, higher admission blood 
glucose was related to case fatality irrespective of the 
diabetes status and type of infarction only in the under-75 
group. For the patients aged 75–84 years, it was only 
true for those without diabetes and STEMI. Admission 
blood glucose was also associated with major cardiac 
complications in both age groups.
Conclusion Admission blood glucose was significantly 
associated with 28- day case fatality in patients with AMI 
aged 65–74 years but not 75–84 years; furthermore, in 
both age groups there was an increased risk of major 
complications. It seems that admission glucose may play 
a rather minor role in terms of case fatality in higher aged 
patients with AMI.
INTRODUCTION
Elevated admission blood glucose levels 
are common in patients hospitalised for 
acute myocardial infarction (AMI); the 
prevalence of admission hyperglycaemia in 
epidemiological studies for these patients 
ranges from 40% to >58%.1 2 Several studies 
and meta- analyses further suggested that 
hyperglycaemia on admission is an indepen-
dent risk factor for adverse outcomes and 
mortality among patients hospitalised with 
AMI.3 4
Timmer et al5–8 demonstrated that a higher 
glucose level on admission is independently 
associated with increased sensitivity to isch-
aemia reperfusion injury such as impaired 
initial flow in the infarct- related artery. 
Blood glucose level was also described as an 
independent prognostic factor for impaired 
microvascular function or the no- reflow 
phenomenon.9 In addition, some studies 
showed that patients with hyperglycaemia 
have a higher Killip class and thus mortality 
risk.10 Moreover, a larger infarct size and worse 
left ventricular (LV) function were linked to 
a higher glucose level,11 and an addition of 
blood glucose levels improves the predictive 
Strengths and limitations of this study
 ► This study was observational and was limited to 
German patients aged 65–84 years old with incident 
acute myocardial infarction.
 ► The analysis was limited to admission blood glucose 
values only and it cannot be ruled out that some 
patients with hyperglycaemia without a history of 
diabetes are true diabetes cases who have not been 
diagnosed before.
 ► Multivariable analysis was adjusted for several risk 
factors, thus residual confounding cannot be entirely 
excluded.
 ► Data were collected within the framework of a 
population- based myocardial infarction registry.
 ► Important risk factors such as comorbidities, in- 
hospital treatment and complications were included 
in the analysis.
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ability of the Global Registry of Acute Coronary Events 
risk score.12 13
The majority of the existing studies were conducted in 
the pre- reperfusion era,3 14–16 were focused on patients 
with or without diabetes17 18 or included the whole spec-
trum of acute coronary syndromes in their analysis.19 So 
far, only a few studies examined the association between 
admission blood glucose levels and short- term outcomes 
(including in- hospital mortality and cardiac complica-
tions) in older people.20 Furthermore, the association 
between admission glucose in certain subgroups of older 
patients with AMI is missing so far. Therefore, the aim 
of this study including all non- selected hospitalised cases 
with incident AMI was to investigate the association of 
admission glucose on 28- day case fatality and cardiac 
complications in patients aged 65–84 years old under-
going non- invasive and invasive therapy. Analyses strat-
ified according to diabetes, age and type of infarction 
were conducted to determine the importance of admis-
sion blood glucose for the short- term prognosis of certain 
patient subgroups with AMI.
METHODS
Study design and data source
Data for the present observational study came from the 
population- based KORA (Cooperative Health Research in 
the Region of Augsburg) Myocardial Infarction Registry 
(Bavaria, Germany), which was implemented in October 
1984 as part of the WHO MONICA (Monitoring Trends 
and Determinants in Cardiovascular Disease) Project. 
Since then all cases of fatal and non- fatal AMI occurring 
among the residents of the study area (city of Augsburg 
and two adjacent counties) aged 25–74 years old, who 
were admitted to one out of eight hospitals in the study 
area have been continuously registered. The registry was 
included into the KORA framework when the MONICA 
Project was terminated in 1995. Detailed information on 
methods of case identification, diagnostic classification of 
events and quality control of the data has been described 
in previous publications.21–23 Diagnostic criteria for AMI 
case identification were adapted to the joint statement 
of the European Society of Cardiology and American 
College of Cardiology and applied since 2001.24 From 
2009 onwards, the registry was extended for the elderly 
up to 84 years.
Data collection and measurements
Patients with AMI, who have survived for at least 24 hours 
after hospitalisation, were interviewed by specially trained 
nurses using a standardised questionnaire. Information 
on sociodemographic data, acute symptoms, cardio-
vascular risk factors and history of several diseases was 
collected. Diabetes status (yes/no) was based on what 
was known on admission only. Data on AMI character-
istics, drug treatment before and during hospital stay, 
medication use at discharge, in- hospital adverse events, 
including ventricular fibrillation, cardiogenic shock, 
cardiac arrest, recurrent MI, and pulmonary oedema, 
were provided by chart review. Additionally, laboratory 
parameters including the first blood glucose level at 
admission (referred as admission glucose level), ECG 
data and the process of care in hospital were also deter-
mined. The kind of reperfusion therapy (thrombolysis, 
percutaneous coronary intervention (PCI) and coronary 
artery bypass grafting (CABG)) was documented.
Study population
Between 1 January 2009 and 31 December 2016, a total 
of 7681 patients aged 65–84 years were admitted to one 
of the hospitals in the study region due to an AMI. Of 
those, 1803 patients had a reinfarction and 9 patients had 
missing information on infarction history and were there-
fore excluded. Furthermore, we excluded 255 patients 
without data on admission glucose level and 84 patients 
with missing covariates information. This resulted in a 
total of 5530 patients (3514 men, 2016 women) with inci-
dent AMI for analysis.
Patient and public involvement
Patients and the public were not involved in the research 
process.
Outcomes
The primary endpoint of the study was case fatality within 
28 days. A multiple logistic regression model was used to 
assess the association between the first admission glucose 
level and 28- day case fatality (yes/no). The secondary 
endpoint was a combined endpoint of in- hospital compli-
cations including cardiac arrest, recurrent infarction, 
pulmonary oedema, cardiogenic shock, ventricular 
tachycardia, ventricular bradycardia and ventricular 
fibrillation.
Statistical analysis
Continuous data were expressed as mean values and SD 
as well as median and IQR (25th and 75th quintile) in 
case of non- normal distribution. Categorical data were 
described with absolute values and percentages. Χ2 test 
was used to test differences in prevalence. The two- sided 
Welch’s t- test was used to compare means.
Due to the large number of missing values presented 
in table 1, we used multiple imputation before regres-
sion. Since the missing mechanism was not completely 
at random, this approach minimised bias of the effect 
estimates and increased statistical power. Multivariable 
analyses were performed for the whole sample and also 
stratified by age groups (65–74/75–84 years), diabetes 
status (yes/no) and type of infarction (ST- elevation MI 
(STEMI)/non- STEMI (NSTEMI)) using forward stepwise 
logistic regression to identify variables independently 
associated with 28- day case fatality (yes/no) after AMI. 
The variables age (only in the analysis including the total 
sample) and sex were forced into each model during the 
variable selection procedure. The significance criterion 
for staying in the final model was chosen as p<0.05. The 
association between admission blood glucose level and 
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the primary endpoint was adjusted for sex and age in the 
first model. The second model included previous factors 
and any reperfusion therapy (yes/no), treatment with 
ACE inhibitor (yes/no), beta- blocker (yes/no), lipid- 
lowering drug (yes/no), antiplatelets during hospital stay 
(yes/no), insulin (yes/no), cardiac arrest during hospital-
isation (yes/no), any other complication during hospital 
stay (recurrent infarction, ventricular fibrillation, ventric-
ular tachycardia, bradycardia, pulmonary oedema and 
cardiogenic shock), and diabetes (yes/no).
In logistic regression analysis investigating the associ-
ation between admission blood glucose level and the 
secondary endpoint, the first model included admis-
sion blood glucose, age and sex. The second model was 
adjusted additionally for diabetes (yes/no), any reperfu-
sion therapy (yes/no), treatment with ACE inhibitor (yes/
no), beta- blocker (yes/no), lipid- lowering drug (yes/no), 
antiplatelets during hospital stay (yes/no) and insulin 
(yes/no). ORs and 95% CI interval were computed per 1 
SD increase of admission blood glucose level.
We conducted a formal test to identify an interaction 
with sex, age, diabetes and MI type. The test showed 
significant interaction with age and diabetes. Due to a 
significant interaction with age, the sample was stratified 
into two age groups: ‘young- old’ patients (65–74 years) 
and ‘old’ patients (75–84 years) (figure 1). In addition, 
stratified analyses were conducted for patients with and 
without diabetes, and for patients with STEMI/NSTEMI.
We used restricted cubic splines with different numbers 
of knots for testing the linearity assumption of the appro-
priate multivariable logistic model. For all investigations, 
a significance level of 5% was applied. Analyses were 
performed using R V.3.5.2.
RESULTS
In total, the study sample consisted of 5530 women and 
men aged 65–84 years. There were 292 (7.9%) deaths 
within 28 days among 3709 patients aged 65–74 years 
and 209 (11.5%) deaths among 1821 patients aged 75–84 
years. The median admission glucose level was 94.0 mg/
dL (IQR 68.0–138.0 mg/dL) and 37.9% of the patients in 
the total sample had known diabetes.
The baseline characteristics of the patients according 
to the age groups are shown in table 1. The older age 
group was associated with a higher proportion of female 




(n=5530)65–74 (n=3709) 75–84 (n=1821)
Female sex 1185 (31.9%) 831 (45.6%) <0.001 2016 (36.5%)
Hypertension 3060 (82.5%) 1602 (88.0%) <0.001 4662 (84.3%)
Lipid disorder 2238 (60.3%) 906 (49.8%) <0.001 3144 (56.9%)
Smoking status
  Smoker 674 (18.2%) 121 (6.6%) 795 (14.4%)
  Ex- smoker 1245 (33.6%) 533 (29.3%) 1778 (32.2%)
  Never smoker 1291 (34.8%) 792 (43.5%) 2083 (37.7%)
  Missing 499 (13.5%) 375 (20.6%) 874 (15.8%)
Glucose level on admission (mg/dL) (median (IQR)) 92.0 (71.0) 97.0 (71.0) 0.521 94.0 (70.0)
Peak glucose level (mg/dL) (median (IQR)) 98.0 (60.0) 95.0 (81) <0.001 97.0 (87.0)
Cardiac arrest before hospitalisation 147 (4.0%) 41 (2.3%) 188 (3.4%)
  Missing 220 (5.9%) 159 (8.7%) 379 (6.9%)
LVEF <30% 197 (5.3%) 169 (9.3%) 366 (6.6%)
  Missing 987 (26.6%) 288 (15.8%) 1275 (23.1%)
Diabetes 1376 (37.1%) 721 (39.6%) 0.077 2097 (37.9%)
Type of Infarction
  STEMI 1189 (32.1%) 440 (24.2%) <0.001 1629 (29.5%)
  NSTEMI 1967 (53.0%) 898 (49.3%) 2865 (51.8%)
  Bundle branch block 316 (8.5%) 220 (12.1%) 536 (9.7%)
  Not defined 237 (6.4%) 263 (14.4%) 500 (9.0%)
Typical symptoms 2896 (78.1%) 1218 (66.9%) 4114 (74.4%)
  Missing 54 (1.5%) 29 (1.6%) 83 (1.5%)
AMI, acute myocardial infarction; LVEF, left ventricular ejection fraction; NSTEMI, non- ST- elevation myocardial infarction; STEMI, ST- elevation 
myocardial infarction.
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patients and a higher frequency of patients with a history 
of hypertension. In the younger age group, a higher prev-
alence of STEMI type as well as NSTEMI type than in the 
older age group was observed. Patients in the younger 
age group showed a higher prevalence of lipid disorders 
in comparison with the older age group.
Treatment during hospital stay according to the age 
groups is shown in table 2. More young- old patients less 
likely received ACE inhibitors, beta- blockers and nitrates. 
On the other hand, older patients were more often 
treated with calcium channel blockers and angiotensin II 
antagonists. There was no difference in treatment with 
lipid- lowering drugs, antiplatelets and insulin. At least 
one recanalisation therapy (PCI, CABG or thrombolysis) 
was more likely performed in the young- old compared 
with the older patients.
Major complications in patients with AMI occurring 
during hospital stay are listed in table 3. Frequency of 
in- hospital cardiac arrest was significantly higher in 
the older patients’ group. Regarding other in- hospital 
complications including cardiogenic shock, pulmonary 
oedema, ventricular fibrillation, tachycardia and reinfarc-
tion there was no significant difference between the two 
age groups.
In the whole sample, as it is presented in table 4, admis-
sion blood glucose was significantly associated with 28- day 
case fatality: per 1 SD increase in admission blood glucose 
level the OR for 28- day mortality was 1.33 (95% CI: 1.19 
to 1.50). In the young- old group there was also a signif-
icant relationship; per 1 SD increase of blood glucose 
the OR for 28- day case fatality was 1.40 (95% CI: 1.21 to 
1.62). Among the older patients, there was no significant 
Figure 1 Flow chart diagram of study sample selection. Inclusion process for study sample with numbers and reasons for 
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association in the fully adjusted model (OR 1.21; 95% CI: 
0.98 to 1.50).
In addition, blood glucose levels at admission were 
independently associated with major in- hospital complica-
tions in the total sample and in both age groups (table 4). 
Among all patients, the OR for any major complication 
was 1.25 (95% CI: 1.17 to 1.35) per 1 SD increase of blood 
glucose level; among the patients aged 65–74 years and 
75–84 years, the ORs were 1.24 (95% CI: 1.13 to 1.35) and 
1.29 (95% CI: 1.14 to 1.47) per 1 SD increase of blood 
glucose level, respectively.
Admission glucose level was significantly associated with 
higher 28- day mortality and hospital complications, irre-
spective of diabetes status in both the young- old and old 
groups (except the association with the 28- day mortality 
in the older group) (table 4). In patients with STEMI but 
not with NSTEMI, a significant association with 28- day 
case fatality could be observed for both young- old and 
older patients. Regarding in- hospital complications, in 
patients with STEMI, a significant relationship could be 
found for the older patients (OR 1.68; 95% CI: 1.24 to 
2.27). In patients with NSTEMI, a significant association 
with in- hospital complications could be shown for both 
the young- old (OR 1.17; 95% CI 1.04 to 1.33) and old 
groups (OR 1.20; 95% CI 1.01 to 1.43).
DISCUSSION
In this real- world study including all consecutive hospi-
talised, unselected cases with incident AMI in patients 
65–84 years of age, 28- day case fatality was associated 
with increasing blood glucose concentrations measured 




(n=5530)65–74 (n=3709) 75–84 (n=1821)
Drug treatment of patients with AMI
  Antiplatelets 3661 (98.7%) 1806 (99.1%) 0.158 5467 (98.8%)
  Ca- antagonists 1343 (36.2%) 748 (41.1%) <0.001 2091 (37.8%)
  ACE inhibitors 3007 (81.1%) 1337 (73.4%) <0.001 4344 (78.5%)
  Beta- blockers 3492 (94.1%) 1683 (92.4%) 0.016 5175 (93.6%)
  Nitrates 2948 (79.5%) 1237 (67.9%) <0.001 4185 (75.7%)
  Angiotensin II antagonists 404 (10.9%) 327 (17.9%) <0.001 731 (13.2%)
  Other antihypertensives 635 (17.1%) 395 (21.7%) <0.001 1030 (18.6%)
  Statins 3284 (88.5%) 1614 (88.6%) 0.956 4898 (88.6%)
  Insulin 1250 (33.7%) 610 (33.5%) 0.904 1860 (33.6%)
Recanalisation therapy of patients with AMI
  At least one recanalisation therapy 2941 (79.3%) 1271 (69.8%) <0.001 4212 (76.2%)
  PCI 2294 (61.8%) 1064 (58.4%) 0.015 3358 (60.7%)
  Bypass 672 (18.1%) 236 (13.0%) <0.001 908 (16.4%)
  Thrombolytic therapy 160 (4.3%) 8 (0.4%) <0.001 168 (3.0%)
AMI, acute myocardial infarction; PCI, percutaneous coronary intervention.





(n=5530)65–74 (n=3709) 75–84 (n=1821)
Cardiac arrest in hospital 403 (10.9%) 256 (14.1%) <0.001 659 (11.9%)
Cardiogenic shock 253 (6.8%) 149 (8.2%) 0.075 402 (7.3%)
Pulmonary oedema 172 (4.6%) 85 (4.7%) 1 257 (4.6%)
Bradycardia 225 (6.1%) 99 (5.4%) 0.380 324 (5.9%)
Ventricular fibrillation 121 (3.3%) 50 (2.7%) 0.336 171 (3.1%)
Ventricular tachycardia 149 (4.0%) 82 (4.5%) 0.437 231 (4.2%)
Reinfarction 92 (2.5%) 33 (1.8%) 0.140 125 (2.3%)
28- day case fatality 292 (7.9%) 209 (11.5%) <0.001 501 (9.1%)
AMI, acute myocardial infarction.












pen: first published as 10.1136/bm


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm




7Mamadjanov T, et al. BMJ Open 2021;11:e046641. doi:10.1136/bmjopen-2020-046641
Open access
at hospital admission. The risk of death in the young- old 
patients (65–74 years) increased significantly with 
increasing blood glucose levels, but in the older patients’ 
group (75–84 years) no independent association was 
found. In addition, admission glucose was significantly 
associated with a higher 28- day mortality in the total 
sample of patients with and without diabetes, and in 
patients with STEMI. The risk of major in- hospital compli-
cations after incident AMI was also related to higher 
admission blood glucose levels in both age groups, in the 
total sample of patients with and without diabetes, and 
patients with STEMI and NSTEMI.
Previous studies have demonstrated that elevated 
blood glucose on admission is common in patients with 
AMI and is independently associated with a higher risk 
of in- hospital mortality and in- hospital complications, 
such as cardiac arrest, cardiogenic shock and pulmo-
nary oedema regardless of diabetes status.25–27 Although 
numerous studies have documented this association,20 28–30 
the impact of admission blood glucose on short- term 
mortality and in- hospital complications in older patients 
with AMI remains underappreciated so far.
In a large population- based study including patients 
with AMI aged 65 years and older,20 glucose levels were 
associated with 30- day case fatality in patients without 
known diabetes (referent: glucose ≤110 mg/dL; range 
from glucose >110–140 mg/dL: HR 1.17; 95% CI: 1.11 
to 1.24; to glucose >240 mg/dL: HR 1.87; 95% CI: 1.75 
to 2.00). In a nationally representative study of patients 
(median age 67 years) hospitalised with AMI in China, 
Zhao et al30 reported that both moderate and severe 
hyperglycaemia (blood glucose ≥11.1 mmol/L) on admis-
sion were associated with an elevated risk of in- hospital 
mortality among both patients without and with diabetes. 
Fujino et al29 analysed the short- term outcome of acute 
hyperglycaemia on admission (≥200 mg/dL) and chronic 
hyperglycaemia defined by an HbA1c ≥6.5% in a small 
sample of patients with AMI and reported that acute 
hyperglycaemia but not chronic hyperglycaemia was an 
independent predictor of in- hospital mortality.
Several prior studies examined the association between 
hyperglycaemia on admission and complications of AMI. 
Dziewierz et al25 analysed data of elderly patients with AMI 
of the Poland’s Krakow Registry and found that hypergly-
caemia on admission was related to an increased risk of 
pulmonary oedema and heart rhythm/conduction distur-
bances in both patients with and without diabetes. In 
another study, Kim et al27 found a significant association 
between hyperglycaemia and life- threatening complica-
tions during hospitalisation such as cardiogenic shock, 
decreased haemoglobin level (haemoglobin ≥0.5 g/L), 
atrioventricular block, ventricular tachycardia and atrial 
fibrillation. Besides, they observed that a higher age of 
patients (≥75 years), female sex, STEMI, low LV function, 
low revascularisation ratio, larger infarct size and inflam-
mation were related to hyperglycaemia on admission.
The results of the present study confirm the find-
ings regarding a strong association between admission 
blood glucose and short- term mortality as well as in- hos-
pital complications in patients with AMI independent 
of diabetes status. Contrary to our study, prior studies 
did not evaluate how the relationship between admis-
sion glucose and outcomes varies between different age 
groups or other AMI subgroups in higher aged patients. 
The present study therefore expands the current under-
standing of the relevance of admission glucose regarding 
adverse outcomes in subgroups of older patients with 
AMI. Further studies on this issue are necessary to confirm 
or refute our findings.
The present data indicated that admission glucose 
had different impacts on adverse short- term outcomes 
in elderly patients with STEMI versus NSTEMI. Prior 
studies investigating the relevance of admission glucose 
on outcomes were mostly conducted in patients with 
STEMI31–33 or included both patients with STEMI and 
NSTEMI20 34 35 ; only a few studies were conducted in 
NSTEMI samples.36 In addition, studies on this issue 
conducted in elderly patients with AMI are scarce.37 For 
example, a meta- analysis including six cohort studies 
reported that elevated admission glucose (≥6.1–11.1 
mmol/L) was significantly associated with short- term 
mortality in patients with STEMI without diabetes (RR 
4.38; 95% CI 3.23 to 5.94).38 In another study conducted 
in patients with NSTEMI undergoing PCI, admission 
blood glucose was a predictor of 30- day major adverse 
cardiovascular events (MACE), irrespective of diabetes 
status.36 Our results suggested that admission glucose 
might be a predictor of short- term mortality and in- hos-
pital complications in patients with STEMI aged 65–84 
years old, while in patients with NSTEMI it was associated 
with in- hospital complications only.
The increased mortality related to high admission 
glucose levels in patients with AMI has been linked 
to different pathophysiological mechanisms. There is 
evidence for the toxic effects of hyperglycaemia on cell 
function, because acute high blood glucose might induce 
oxidative stress, most likely via generation of free radicals.2 
Moreover, hyperglycaemia inhibits metabolic processes 
in the myocardium and induces apoptosis in cardiomy-
ocytes. Chang et al39 showed an association between high 
glucose level and sFas serum levels, which is a valuable 
biomarker of the physiological response to ischaemia.
Stress hyperglycaemia in patients with MI could also 
be associated with adverse outcomes due to its ability to 
increase systemic inflammation and activation of stress 
responsive kinases. Recently, Marfella et al40 demonstrated 
an association between inflammatory markers and func-
tional cardiac outcome in patients with an incident MI. In 
that study, hyperglycaemia was associated with amplified 
inflammatory immune reactions and worse functional 
cardiac outcome.
Moreover, hyperglycaemia is strongly associated with 
impaired coronary flow before reperfusion and has been 
related to enhanced thrombin formation, platelet acti-
vation and fibrin clot resistance to lysis. Hyperglycaemia 
has been linked to increased sensitivity to ischaemia 
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reperfusion injury.5 41 These pathological processes may 
vary with age, that could explain, at least in part, our 
results.
It is well known that age is a risk factor for cardiovas-
cular disease and an independent risk factor for mortality 
and adverse outcomes after AMI. For example, Shechter 
et al42 demonstrated that patients with AMI over 80 years 
had more MACE (including reinfarction, post- infarction 
angina, ischaemic stroke, high- degree atrioventricular 
block, acute renal failure and major bleeding) in- hos-
pital and a fourfold to fivefold higher mortality rate than 
younger patients. Furthermore, age is related to frequent 
complications and side effects of treatment interventions 
and pharmacotherapy.43 Additionally, the haemodynamic 
impact of a given infarct size may be more pronounced in 
the elderly as a result of reduced cardiac reserve.44 There 
is also a greater likelihood of comorbid illnesses with 
advancing age, which contribute to poorer outcomes.45 
The non- significant association between admission 
glucose levels and 28- day mortality in the age group 75–84 
years in our study may be attributed to the fact that these 
patients suffered more often from comorbidities and 
were more severely ill (eg, higher complication rate, a 
higher proportion of patients with an LV ejection fraction 
<30%) compared with the younger age group; it might be 
thinkable that admission glucose values might not have a 
major influence on the case fatality in this group.
Several important limitations of the present study 
should be acknowledged. First, our study was observa-
tional and non- randomised by nature and therefore, 
causality could not be evaluated. Second, the analysis was 
limited to admission blood glucose values. In patients 
without diabetes, admission blood glucose alone without 
HbA1c values to test for undiagnosed diabetes or pre- 
diabetes and without post- discharge tests to assess the 
glycaemic state after the drop of stress during hospital 
admission, the meaning and interpretation of admission 
hyperglycaemia in clinical practice is difficult.46–49 We 
cannot exclude the possibility that the outcome in the 
group without diabetes was driven by pre- diabetes or undi-
agnosed diabetes. Furthermore, there is a lack of infor-
mation on the effect of in- hospital treatment regarding 
hyperglycaemia and hypoglycaemia, and how glucose 
levels during hospital stay affected adverse outcomes. 
Additionally, in our study, we did not assess major comor-
bidities, which can increase the risk of death (eg, lung 
disease, chronic renal failure or peripheral vascular 
disease) and for this reason our results should be inter-
preted with caution. Although our multivariable analysis 
was adjusted for several risk factors, residual confounding 
cannot be entirely excluded. Finally, our study was limited 
to German patients aged 65–84 years old with incident 
AMI, therefore it remains uncertain if our results apply to 
other populations and age subgroups of patients.
The present study is characterised by several strengths. 
Data were collected within the framework of a population- 
based MI registry, and the consecutively admitted patients 
included from the general population presenting with 
first AMIs were registered according to a standardised 
protocol. Furthermore, important risk factors, in- hospital 
treatment, complications and types of infarction were 
included in our analysis.
CONCLUSIONS
Admission blood glucose was significantly associated with 
28- day case fatality in patients with AMI aged 65–74 years 
but not 75–84 years; furthermore, in both age groups 
there was an increased risk of major complications. After 
stratification for diabetes and type of infarction, admis-
sion blood glucose was significantly related to case fatality 
irrespective of the diabetes status and type of infarction 
only in the patients aged 65–74 years. Thus, it is likely 
that admission glucose plays only a minor role in terms 
of case fatality in higher aged patients with AMI. The 
older the patients are the more comorbidities they may 
have and the sicker these patients may be when admitted 
to hospital. The probability that these patients die from 
these conditions seems to be higher than that they die as 
a result of increased admission glucose.
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